RT Journal Article
SR Electronic
T1 Pharmacokinetics and safety of XAV-19, a swine glyco-humanized polyclonal anti-SARS-CoV-2 antibody, for COVID-19-related moderate pneumonia: a randomized, double-blind, placebo-controlled, phase IIa study
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.04.15.21255549
DO 10.1101/2021.04.15.21255549
A1 Benjamin Gaborit
A1 Eric Dailly
A1 Bernard Vanhove
A1 Régis Josien
A1 Karine Lacombe
A1 Vincent Dubee
A1 Virginie Ferre
A1 Sophie Brouard
A1 Florence Ader
A1 Marie-Anne Vibet
A1 Aurélie Le Thuaut
A1 Richard Danger
A1 Laurent Flet
A1 Anne Omnes
A1 Laetitia Berly
A1 Anne Chiffoleau
A1 Alexandra Jobert
A1 Odile Duvaux
A1 François Raffi
A1 POLYCOR trial group
YR 2021
UL http://medrxiv.org/content/early/2021/04/20/2021.04.15.21255549.abstract
AB Background We assessed the pharmacokinetics and safety of XAV-19, a swine glyco-humanized polyclonal antibody against SARS-CoV-2, in COVID-19-related moderate pneumonia. In vitro, 100% neutralization activity is seen with XAV-19 concentrations above 5 μg/mL.Methods In this phase 2a trial, adults with COVID-19-related moderate pneumonia of ≤10 days duration were randomized to infusion of XAV-19 0.5 mg/kg at day 1 and day 5 (group 1), 2 mg/kg at day 1 and day 5 (group 2), 2 mg/kg at day 1 (group 3) or placebo.Results Eighteen patients (n=7 for group 1, n=1 for group 2, n=5 for group 3, and n=5 for placebo) were enrolled. Baseline characteristics were similar across groups, XAV-19 serum concentrations (μg/mL, median, range) at Cmax and at day 8 were 9.1 (5.2-18.1) and 6.4 (2.8-11.9), 71.5 and 47.2, and 50.4 (29.1-55.0) and 20.3 (12.0-22.7) for groups 1, 2 and 3, respectively (p=0.012). Terminal half-life (median, range) was estimated at 11.4 (5.5-13.9) days for 2 mg/kg of XAV-19 at day 1. Serum XAV-19 concentrations were above the target concentration of 10 μg/mL (tow fold the in vitro 100% inhibitory concentration [IC100]) from the end of perfusion to more than 8 days for XAV-19 2 mg/kg at day 1. No hypersensitivity or infusion-related reactions were reported during treatment, there was no discontinuation for adverse events and no serious adverse events related to study drug.Conclusions Single intravenous dose of 2 mg/kg of XAV-19 demonstrated high serum concentrations, predictive of potent durable neutralizing activity with good tolerability.Trial registration ClinicalTrials.gov Identifier: NCT04453384Main point In this first-in-human trial including patients with COVID-19-related pneumonia, a single 2mg/kg dose of a swine glyco-humanized polyclonal anti-SARS-CoV-2 antibody, achieved serum concentrations above the target of neutralization threshold for 8 days in all patients, with good tolerability and safety.Competing Interest StatementBG reports receipt non-financial support from Gilead Sciences and MSD, outside of the submitted work. BV is an employee and chief scientific officer/operating officer of Xenothera, and own shares and holds share options in Xenothera. KL reports receipt of personal fees from and non-financial support from Abbvie, Chiesi, Healthcare, Janssen, MSD and ViiV outside of the submitted work. VD reports receipt non-financial support from Gilead Sciences, MSD and Sanofi-Pasteur, outside of the submitted work. OD is a cofounder of Xenothera, is the CEO of Xenothera and own shares and holds share options in Xenothera. FR reports receipt of personal fees from Abbvie, Gilead Sciences, Janssen, MSD and ViiV Healthcare, outside of the submitted work. All other authors report no conflict of interest.Clinical TrialClinicalTrials.gov Identifier: NCT04453384Funding StatementThis work was funded by Nantes University Hospital Research Department with support from Public Investment Bank in the framework of the Investment for the Future programme and XenotheraAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was conducted in accordance with good clinical practice procedures, all applicable regulatory requirements, and the guiding principles of the Declaration of Helsinki. The study protocol was reviewed and approved by the Ethics Committee OUEST VI (20.06.15.31306). All patients provided written informed consent before the entry in the study. The study is registered with ClinicalTrial.gov, NCT04453384.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data analysed and presented in this study are available from the corresponding author on reasonable request, providing the request meets local ethical and research governance criteria after publication. Data collected during the study may be processed electronically, in accordance with the requirements of the CNIL (compliance with reference methodology MR001).